The Petri Dish: 2seventy bio pauses trial after patient death; Biogen begins a contentious board shakeup

2seventy bio, the cancer-focused spinout of bluebird bio, has paused a clinical trial in acute myeloid leukemia after a child died at Seattle Children’s. Plus, other life sciences news you may have missed.